Author:
Mitterer A.,Matthiessen H. P.,Gritsch H.,Varadi K.,Siekmann J.,Schnecker K.,Plaimauer B.,Kaliwoda M.,Purtscher M.,Woehrer W.,Mundt W.,Muchitsch E.-M.,Suiter T.,Ewenstein B. M.,Ehrlich H. J.,Schwarz H. P.,Turecek P. L.
Abstract
SummaryBaxter has developed a recombinant therapy for treating von Willebrand‘s disease. Recombinant VWF is co-expressed with the rFVIII in CHO cells used to produce the rFVIII product Advate. This rVWF is used as a drug component for a rVWF-rFVIII complex drug product. CHO cells produce partially processed and partially un-processed rVWF still containing the pro-peptide. In order to make a consistent preparation containing mature and processed rVWF only, rVWF is exposed to recombinant furin to remove the pro-peptide. Recombinant
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献